Glaukos (NYSE:GKOS) 株価情報

Glaukos

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Glaukos Corp

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) has outperformed the market over the past 5 years by 8.36% on an annualized basis producing an average annual return of 23.52%. Currently, Glaukos has a market capitalization of $6.95 billion. 
Buying $100 In GKOS: If an investor had bought $100 of GKOS stock 5 years ago, it would be worth $205.69 today based on a price of $126.07 for GKOS at the time of writing.
<h3>Glaukos's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740408314_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

GKOS

Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today

On Monday, Glaukos Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) received the &#8220;Day 74&#8221; notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-gen corneal cross-linking iLink therapy for keratoconus, a sight-threatening corneal disease, is sufficiently complete to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43908675/glaukos-announces-fda-acceptance-of-nda-submission-for-epioxa" rel="noreferrer noopener">permit a substantive review</a>.
The Prescription Drug User Fee Act goal date for the completion of the FDA&#8217;s review of the Epioxa NDA is set for Oct. 20, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43883818/glaukos-delivers-mixed-q4-results-analyst-sees-growing-investor-interest-during-transition" rel="noreferrer noopener">Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition</a>
&#8220;The acceptance of the Epioxa NDA represents another important step in being able to provide keratoconus patients and the ophthalmic community with the first FDA-approved, non-invasive corneal cross-linking drug therapy that does not require removal of the corneal epithelium, the outermost layer of the front of the eye,&#8221; said Glaukos CEO Thomas Burns.
The NDA submission includes data from two Phase 3 pivotal Epioxa trials, which achieved the pre-specified primary efficacy endpoints and demonstrated favorable tolerability and safety profiles.
Glaukos&#8217; corneal cross-linking iLink therapies use proprietary, bio-activated drug formulations designed to strengthen corneal tissue and halt the progression of keratoconus.
Glaukos&#8217; first-generation iLink therapy, known as Photrexa, or&nbsp;Epi-off, is the first and only FDA-approved therapy that has been shown to slow or halt disease progression.
Epioxa utilizes a proprietary, novel drug formulation designed to penetrate the epithelial layer of the cornea, a stronger UV-A irradiation protocol, and supplemental oxygen to enhance cross-linking.
Price Action: GKOS stock is up 25% at $157.36&nbsp;during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43890152/insulets-strong-q4-highlights-surging-omnipod-demand-and-growth-potential-analyst-sees-continued-growth-in-2025" target="_blank" rel="noreferrer noopener">Insulet&#8217;s Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst</a></li>
</ul>
Image: Shutterstock

Health Care

Movers

General

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

The company has received the "Day 74" notification from the FDA acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a sight-threatening corneal disease, is sufficiently complete to permit a substantive review.&nbsp;

Glaukos Secures FDA Acceptance Of NDA Submission For Epioxa

All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about<a href="https://www.benzinga.com/25/02/43877634/us-stocks-fluctuate-in-preopen-volatility-doesnt-equal-financial-loss-unless-you-sell-says-expert"> the economic outlook.&nbsp;</a>
The University of Michigan consumer sentiment index fell to 64.7 in January, a decline of 10% and a steeper drop than expected. The 5-year inflation outlook in the survey is the highest since 1995 at 3.5% 
Existing home sales sank by 4.9% to a seasonally adjusted rate of 4.08 million in January, the sharpest decline in seven months, according to Trading Economics.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/02/43884153/us-services-drop-sharply-darkening-picture-of-high-prices-uncertainty-economist-says">US Services Drop Sharply: &#8216;Darkening Picture&#8217; Of High Prices, Uncertainty, Economist Says</a>
February's flash S&amp;P Global PMIs released <a href="https://www.benzinga.com/general/market-summary/25/02/43884153/us-services-drop-sharply-darkening-picture-of-high-prices-uncertainty-economist-says">Friday morning </a>revealed a sharp, unexpected drop in services and raised concerns about the health of the private sector.&nbsp;
"The upbeat mood seen among US businesses at the start of the year has evaporated, replaced with a darkening picture of heightened uncertainty, stalling business activity and rising prices," said Chris Williamson, chief business economist at S&amp;P Global Market Intelligence.&nbsp;
Natural gas futures rose another 4.5% Friday to $4.3/MMBtu, hitting a 25-month high as cold weather increased heating demand and disrupted production. The United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>), tracking the daily price movements of natural gas futures contracts, climbed 3.2%.&nbsp;
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was volatile as crypto markets reacted to a $1.4 billion Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) hack targeting Bybit&#8217;s cold wallet, <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43886224/bybit-founder-confirms-1-4-billion-ethereum-hack-blames-masked-transaction">one of the largest</a> security breaches in recent history.
<h2 class="wp-block-heading">Friday's Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,753.44</td>
<td>-1.05%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,069.73</td>
<td>-0.78%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,739.57</td>
<td>-0.99%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,231.48</td>
<td>-1.34%</td>
</tr>
</tbody>
</table>
</figure>
<h2 class="wp-block-heading">Friday's Stock Movers:&nbsp;</h2>
Shares of UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) slumped nearly 9% after the Wall Street Journal reported the Department of Justice launched an investigation into the company&#8217;s Medicare billing practices.
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Solaris Energy Infrastructure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) </li>
<li>Iamgold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) </li>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) </li>
<li>Glaukos Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) </li>
<li>MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) </li>
<li>The RealReal, Inc. (NASADQ:REAL) </li>
<li>Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>)</li>
<li>Globant S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) </li>
<li>Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) </li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) </li>
</ul>
Companies reporting on Monday included:&nbsp;
<ul>
<li>Domino&#8217;s Pizza Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) </li>
<li>Zoom Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) </li>
<li>Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) </li>
<li>Kosmos Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) </li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) </li>
<li>Hovnanian Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOV#NYSE">HOV</a>) </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43836832/trump-administration-orders-sweeping-pentagon-cuts-defense-sector-stocks-on-watch"> Trump Administration Orders Sweeping Pentagon Cuts: Palantir, Lockheed Martin, General Dynamics Among Stocks On Watch</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Market Summary

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

Real Estate

$BTC

$ETH

CELH

FANG

GLOB

MELI

REAL

RIVN

SMMT

Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday?

On Thursday, Glaukos Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>)&nbsp;reported fourth-quarter sales of $105.5 million, up 28% year over year and beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $100.49 million</a>.
The eye-focused company reported an adjusted EPS loss of 40 cents, narrowing from a 60-cent loss but missing the consensus <a href="https://www.benzinga.com/pressreleases/25/02/b43865644/glaukos-announces-fourth-quarter-and-full-year-2024-financial-results">estimate of a 38-cent loss.</a>
The gross margin for the fourth quarter of 2024 was approximately 73%, compared to approximately 77% in the same period in 2023. Non-GAAP gross margin for the fourth quarter of 2024 was approximately 82%, compared to 84% in the same period in 2023.
The company recorded an operating loss of $28.7 million, compared to an operating loss of $38.6 million a year ago. Adjusted loss from operations in the fourth quarter of 2024 was $18.3 million, compared to an operating loss of $32.4 million in the fourth quarter of 2023.
Glaucoma products recorded net sales of $84.1 million, up 30% year-over-year.
"Our record fourth-quarter results cap off a successful year of global execution of our key commercial and development plans, leaving us well positioned to continue to drive the strong momentum in our business this year and beyond," said Thomas Burns, Glaukos Chairman and CEO.
Also Read: <a href="https://www.benzinga.com/markets/commodities/25/02/43881018/gold-rush-20-heres-how-to-play-the-new-bull-market">Gold Rush 2.0? Here&#8217;s How To Play The New Bull Market</a>
Guidance:&nbsp;Glaukos expects 2025 revenue of $475 million-$485 million versus the consensus of $480.97 million.
William Blair says Glaukos is in the early stages of a major transformation following strong iDose results and a positive 2025 outlook. Analyst Margaret Kaczor Andrew expects the company to hit key reimbursement and commercial milestones in the coming year, driving further growth through 2025.
Glaukos is shifting from a company focused on surgical Minimally invasive glaucoma surgery (MIGS) to a broader business that combines pharmaceuticals and medical devices for eye care.
This transition, along with the recent dip in stock price, could attract more investor interest. William Blair keeps the stock rated Outperform.
Price Action: GKOS stock was down 11.8% at $138.75 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43847808/lenovo-q3-earnings-20-revenue-jump-ai-pcs-and-smartphones-power-market-expansion" target="_blank" rel="noreferrer noopener">Lenovo Q3 Earnings: 20% Revenue Jump, AI PCs and Smartphones Power Market Expansion</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

Guidance

Analyst Ratings

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $153 to $160.

Price Target

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $160

WIIM

Glaukos shares are trading lower after the company reported Q4 Adj Eps miss.

Needham analyst David Saxon maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $149 to $176.

Needham Maintains Buy on Glaukos, Raises Price Target to $176

Glaukos Sees FY25 Revenue $475M-$485M

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.38) by 5.26 percent. This is a 36.51 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $105.500 million which beat the analyst consensus estimate of $100.491 million by 4.98 percent. This is a 28.09 percent increase over sales of $82.365 million the same period last year.

Earnings Beats

Earnings Misses

Glaukos Q4 2024 Adj. EPS $(0.40) Misses $(0.38) Estimate, Sales $105.500M Beat $100.491M Estimate

ACCO

AKAM

ALIT

ALRM

ARDX

ATHM

AXTI

BABA

BAND

BBDC

BBIO

BIGC

BILI

BIRK

BJRI

BKNG

BLDR

CARG

CCRD

CDRO

CENX

CERS

CGAU

COKE

COLD

CPRT

CRAI

CSTM

DAVA

DBRG

DGICA

DGICB

DINO

DVAX

EPAM

ESAB

EXPI

FIVN

FRPT

FYBR

GDYN

GLPI

GMED

GRAL

INDI

INDV

INOD

INSM

IRTC

ITGR

Earnings Scheduled For February 20, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keefe, Bruyette &amp; Woods analyst Meyer Shields upgraded The Travelers Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) from Market Perform to Outperform and raised the price target from $275 to $286. Travelers shares closed at $238.40 on Tuesday. <a href="https://www.benzinga.com/quote/TRV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Janardan Menon upgraded the rating for STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) from Hold to Buy. STMicroelectronics shares closed at $24.41 on Tuesday. <a href="https://www.benzinga.com/quote/STM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Wamsi Mohan upgraded NetApp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) from Underperform to Neutral and raised the price target from $121 to $128. NetApp shares closed at $120.52 on Tuesday. <a href="https://www.benzinga.com/quote/NTAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Anthony Petrone upgrades Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) from Neutral to Outperform and raised the price target from $140 to $200. Glaukos shares closed at $152.96 on Tuesday. <a href="https://www.benzinga.com/quote/GKOS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert upgraded the rating for CervoMed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) from Hold to Buy and announced a $10 price target. CervoMed shares closed at $2.23 on Tuesday. <a href="https://www.benzinga.com/quote/CRVO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NTAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="570" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19082610/image-166-1024x570.png" alt="" class="wp-image-788905" style="width:298px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19082610/image-166-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19082610/image-166-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19082610/image-166-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/19082610/image-166.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43776863/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter-3">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Upgrades

Pre-Market Outlook

Markets

CRVO

NTAP

This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday

Mizuho analyst Anthony Petrone upgrades Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) from Neutral to Outperform and raises the price target from $140 to $200.

Mizuho Upgrades Glaukos to Outperform, Raises Price Target to $200

Glaukos's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) short percent of float has risen 4.05% since its last report. The company recently reported that it has 3.36 million shares sold short, which is 9.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Glaukos Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739379614_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Glaukos has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Glaukos's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Glaukos's peer group average for short interest as a percentage of float is 3.38%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Glaukos's Recent Short Interest

Piper Sandler analyst Matt O'Brien reiterates Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $140 to $180.

Reiteration

Piper Sandler Reiterates Overweight on Glaukos, Raises Price Target to $180

Glaukos's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) short percent of float has risen 18.21% since its last report. The company recently reported that it has 3.04 million shares sold short, which is 8.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.41 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Glaukos Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737983722_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Glaukos has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Glaukos's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Glaukos's peer group average for short interest as a percentage of float is 3.51%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Glaukos?

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) has outperformed the market over the past 5 years by 9.42% on an annualized basis producing an average annual return of 22.7%. Currently, Glaukos has a market capitalization of $8.89 billion. 
Buying $1000 In GKOS: If an investor had bought $1000 of GKOS stock 5 years ago, it would be worth $2,851.94 today based on a price of $161.22 for GKOS at the time of writing.
<h3>Glaukos's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737672311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today

Biotech

Glaukos Announces Clinical Updates For iDose Sustained-Release Procedural Pharmaceutical Platform

Scorpion Capital, on Friday, disclosed a short seller report on TransMedics Group Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), accusing the organ transplant technology company of fraudulent practices, including kickbacks, billing fraud and <a href="https://www.benzinga.com/quote/TMDX" target="_blank" rel="noreferrer noopener">unreported device failures</a>.
Scorpion alleges that TransMedics engages in &#8220;mafia-style&#8221; practices, including coercion, billing fraud, and the manipulation of organ allocation, operating under the guise of a legitimate medical device company.
The report sets a price target of $0.
The company said the allegations are inaccurate and misleading. &#8220;We strongly believe that the claims made in the Scorpion Capital report have no merits and were primarily intended to manipulate the <a href="https://www.benzinga.com/pressreleases/25/01/n42940808/transmedics-responds-to-inaccurate-and-misleading-claims-in-recent-short-seller-report" target="_blank" rel="noreferrer noopener">market for financial gains</a>,&#8221; TransMedics said in a statement.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/management/24/12/42290942/transmedics-ushers-in-new-cfo-tightens-2024-revenue-goals" rel="noreferrer noopener">TransMedics Ushers In New CFO, Tightens 2024 Revenue Goals</a>
The report said TransMedics operates like an airline with a medical device component, trading at an expensive valuation of seven times its last 12 months&#8217; revenue.
By a more relevant metric, enterprise value to product sales, the ratio is 10 times – which Scorpion Capital describes as extraordinarily high, especially <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41608129/organ-transplant-medtech-transmedics-q3-performance-disappoints-analyst-outlines-in" target="_blank" rel="noreferrer noopener">as sales are declining</a>.
This makes TransMedics the most expensive mid-cap medtech company in the U.S. and the third-highest overall, behind Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) and Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), according to Scorpion Capital. 
Even at a more reasonable multiple of 5 times product sales, TransMedics&#8217; stock would drop to the $30 range.
The company has no free cash flow and only recently turned slightly profitable, a trend likely to reverse with declining sales.
Scorpion stated in its report, &#8220;TransMedics is the most extreme and grotesque healthcare fraud we have encountered, not only for its scale, but because it is predicated on the exploitation of the most vulnerable patients &#8212; the terminally ill, desperate for an organ.&#8221;
The short seller <a target="_blank" href="https://scorpionreports.s3.us-east-2.amazonaws.com/TMDX.pdf" rel="noreferrer noopener">alleged</a> that TransMedics &#8220;pushes unsafe, damaged organs rejected by reputable centers, as an unplaced organ means loss of device and aircraft fees, with TransMedics allegedly concealing adverse organ information.&#8221;
Scorpion Capital announced plans to file a Citizen Petition with the FDA, requesting the suspension of Premarket Approval (PMA) for TransMedics&#8217; Organ Care System (OCS). The short seller also said it intends to send a public letter to members of Congress probing abuses in the U.S. organ transplant system.
In April, the FDA granted PMA to the OCS Heart System for use with organs from donors after circulatory death, following a PMA approval of the System after brain death received <a href="https://www.benzinga.com/pressreleases/22/04/n26862717/transmedics-receives-fda-pma-approval-of-ocs-dcd-heart-indication" target="_blank" rel="noreferrer noopener">in September 2021</a>.
Price Action: TMDX stock is down 12.6% at $60.10 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion" target="_blank" rel="noreferrer noopener">Eli Lilly Scoops Up Scorpion Therapeutics&#8217; Early-Stage Cancer Program For $2.5 Billion</a></li>
</ul>
Photo: Tigarto/Shutterstock.com

ISRG

TMDX

Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market

11 analysts have expressed a variety of opinions on Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $156.45, a high estimate of $185.00, and a low estimate of $120.00. Witnessing a positive shift, the current average has risen by 10.26% from the previous average price target of $141.89.
<img src="https://www.benzinga.com/files/images/story/2024/1735671612_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Glaukos is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$153.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$162.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$182.00</td>
<td>-</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$153.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Underweight</td>
<td>$120.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$149.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Allen Gong</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$152.00</td>
<td>$145.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Glaukos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Glaukos's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glaukos analyst ratings.</a>
<h2>All You Need to Know About Glaukos</h2>
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
<h3>Glaukos: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Glaukos's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 23.86%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Glaukos's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -22.15%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Glaukos's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -3.21%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Glaukos's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.32%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.24.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 11 Analyst Ratings Have To Say About Glaukos

Press Releases

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Glaukos Announces Third Quarter 2024 Financial Results

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Comments

Glaukos

ニュース

パートナーシップ

ベンジンガ・グローバル